

# TRACER (S1415CD) NEWSLETTER



August 2017

## STUDY UPDATES

- ✦ As of 8/14/17, we have **736 patients registered across 37 components** (12 out of 13 Cohort components, 7 out of 8 Usual Care components, 9 out of 12 Intervention Arm 3 components, and 9 out of 12 Intervention Arm 4 components).
- ✦ As of 8/14/17, **22 of our 24 intervention components** have completed their order change process and are open for enrollment.

## FORMS UPDATES

The forms set for the S1415CD protocol has been updated. Specific changes include:

- ✦ Questions about current or planned radiation therapy were added to the following forms to help evaluate the eligibility criteria in Section 5.2b and to support exploratory analyses:
  - ✦ S1415CD Onstudy Form Version 1.1
  - ✦ S1415CD CSF and Cancer Treatment Form Version 1.1
  - ✦ S1415CD 12 Month Status Update Form Version 1.1
  - ✦ S1415CD Discontinuation of Initial Systemic Therapy Version 1.1

## CONGRATULATIONS AND THANK YOU TO...

The following sites that have completed their order change process:

- ★ John H Stroger Jr. Hospital of Cook County in Chicago, IL
- ★ Doctor's Cancer Center - Manati in Manati, Puerto Rico

Congratulations to the following sites for enrolling their first patient as of 8/14/17:

- ★ Geisinger Medical Center in Danville, PA
- ★ Dayton Physicians LLC – Good Samaritan North in Dayton, OH
- ★ John H Stroger Jr. Hospital of Cook County in Chicago, IL

Congratulations to **Mercy Hospital Springfield** in Springfield, MO for being our first component to reach **100% of its accrual goal!**

## TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

*This pragmatic trial is designed to test an intervention to increase compliance with guidelines, and generate evidence to assess effectiveness of Primary Prophylactic CSF (PP-CSF) on reducing rates of FN for patients receiving intermediate-risk chemotherapy regimens. TrACER is the first trial of its kind and is sponsored by SWOG, a part of the National Clinical Trials Network. The trial is led by Dr. Scott Ramsey at HICOR and funded in part by PCORI.*

### Contact Us

Site Requirements, including regimen questions: HICOR, [TrACER@fredhutch.org](mailto:TrACER@fredhutch.org); phone: 206-667-7624  
Patient eligibility, study procedures, and data submission: SWOG Data Ops, email: [cancercontrolquestion@crab.org](mailto:cancercontrolquestion@crab.org); phone: 206-652-2267